Evidence map›Paper›PMID 42554933›Full record

ArticleInternational journal of hematology2026

Efficacy and safety of the BEBM (bendamustine, etoposide, busulfan, and melphalan) conditioning regimen for autologous stem-cell transplantation in non-Hodgkin lymphoma.

Sang Hun Lee, Do Young Kim, Ho-Jin Shin

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sang Hun LeeDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0001-6364-2148
Do Young KimDivision of Hematology and Oncology, Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, 179 Gudeok-Ro, Seo-Gu, Busan, 49241, Republic of Korea.ORCID http://orcid.org/0000-0002-9468-8939
Ho-Jin ShinDivision of Hematology and Oncology, Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, 179 Gudeok-Ro, Seo-Gu, Busan, 49241, Republic of Korea. hojinja@hanmail.net.ORCID http://orcid.org/0000-0002-3694-7031

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBendamustine, etoposide, and busulfan (BEB) is a conditioning regimen used for autologous stem-cell transplantation (ASCT) in non-Hodgkin lymphoma (NHL). We investigated whether addition of melphalan (BEBM) could enhance this regimen.

methodsBEBM with melphalan at 50, 70, or 100 mg/m

resultsAll patients experienced grade ≥ 3 hematologic toxicities. Cohort 1 (50 mg/m

conclusionBEBM demonstrated an acceptable safety profile, although significant toxicities were observed at 70 mg/m

Indexed as

Autologous stem-cell transplantationBEBM conditioning regimenBendamustine conditioningMelphalan-based conditioningNon-Hodgkin lymphoma

Identifiers

PMID42554933

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.